Abstract
The management of pain and prevention of end organ damage in patients with sickle cell disease is challenging. Treatment options include antibacterial prophylaxis, appropriate vaccinations, hydroxycarbamide therapy and regular blood transfusion, with the only available cure being haematopoietic stem cell transplantation. Special consideration should be given to patient well-being and management options in low-income countries.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
